Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy — Pietro Ferrara (2021) | RDL Network
Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
Article 2021 en
Authors
PF
Pietro Ferrara
PC
Paolo Angelo Cortesi
DL
Danilo Di Laura
Abstract
1 min read
Compared with aspirin alone, rivaroxaban plus aspirin is cost effective in preventing recurrent cardiovascular events in all patients with CAD or PAD, from the Italian perspective. These results could help clinicians and decision makers to develop improved strategies for cardiovascular disease prevention.
John W. Eikelboom, Jackie Bosch, Stuart J. Connolly, Olga Shestakovska, Gilles R. Dagenais, Robert G. Hart, Darryl P. Leong, Martin O’Donnell, Keith A.A. Fox, Deepak L. Bhatt, John A. Cairns, Christoph Tasto, Scott D. Berkowitz, Nancy Cook Bruns, Eva Muehlhofer, Rafael Díaz, Aldo Maggioni, Salim Yusuf
John W. Eikelboom, Stuart J. Connolly, Jackie Bosch, Gilles R. Dagenais, Robert G. Hart, Olga Shestakovska, Rafael Díaz, Marco Alings, Eva Lonn, Sonia S. Anand, Petr Widimský, Masatsugu Hori, Álvaro Avezum, Leopoldo Soares Piegas, Kelley R. Branch, Jeffrey L. Probstfield, Deepak L. Bhatt, Jun Zhu, Yan Liang, Aldo Maggioni, Patricio López‐Jaramillo, Martin O’Donnell, Ajay K. Kakkar, Keith A.A. Fox, ,
Thomas Vanassche, Peter Verhamme, Darryl P. Leong, Deepak L. Bhatt, Olga Shestakovska, Aldo Maggioni, Keith A.A. Fox, Eva Muehlhofer, Stuart J. Connolly, Salim Yusuf, John W. Eikelboom, Jackie Bosch
Discussion(0)
No comments yet. Be the first to comment.